OS Therapies Incorporated

$1.44

+$0.10 (+7.46%)

Jan 5, 2026

Price History (1Y)

Analysis

OS Therapies Incorporated operates in the healthcare sector within the biotechnology industry. The company's scale is modest, with a market capitalization of $50.71 million and a workforce consisting of only four employees. The financial health of OS Therapies Incorporated is concerning, as evidenced by its margins. The company has reported a gross margin, operating margin, and profit margin of 0.0% each. Additionally, the net income (TTM) stands at -$20,256,220. Returns on equity and assets are also negative, with ROE at -914.0% and ROA at -225.1%. The company's cash position is relatively small at $1.88 million, while debt information is not available. The valuation context of OS Therapies Incorporated is complex, with a forward P/E ratio of -4.33 and an EV/EBITDA ratio of -2.38. This suggests that the market has significant expectations for future performance, which may be challenging given the company's recent financial results.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About OS Therapies Incorporated

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

Visit website →

Key Statistics

Market Cap
$50.71M
P/E Ratio
N/A
52-Week High
$7.00
52-Week Low
$1.12
Avg Volume
373.04K

Company Info

Exchange
ASE
Country
United States
Employees
4